Bench to Bedside: Platelet-rich Plasma—How Do We Adequately “Untranslate” Translational “Breakthroughs” in an After-market Setting?

Regenerative Plasma- und Zelltherapien in der Orthopädie und Unfallchirurgie

“…Ob Plasmatherapien in den kommenden Jahren in Leitlinien und Leistungskataloge der Krankenversicherungen aufgenommen werden, hängt maßgeblich von robusten Forschungsergebnissen und transparenten Produktbeschreibungen ab. Eventuell ist hierfür auch ein "Schritt zurück" nötig, um ein bereits erfolgreich in die Translation überführtes Produkt retrospektiv besser charakterisieren und verstehen zu können [30]. International herrscht bei Therapien mit MSCs eine große Heterogenität in der Nomenklatur, den verfügbaren Zellprodukten und der Anwendung [34].…”

On Patient Safety: Regenerative Medicine—The Hype Amplifies Safety Concerns

“…At present, I recommend a continued skeptical view of regenerative therapies. Let us steer patients interested in such treatments toward clinical trials while waiting for longterm data to emerge (or not) documenting both its safety and efficacy before we begin to make it a routine component of our treatment armamentarium [10,18]. Let us push the FDA to immediately regulate regenerative providers and make the AAOS a leading voice in combatting incomplete or deceptive marketing.…”

CORR Insights®: Prolotherapy Induces an Inflammatory Response in Human Tenocytes In Vitro

“…The refrain demanding additional, highquality studies is tired only because it is so often true. Particularly given that I have written in CORR 1 on the dubious clinical benefit of platelet rich plasma injections (itself arguably a chemotactic form of prolotherapy) [6], why would I suggest high-quality studies of an intervention with a similar track record? Because providers and therapists are performing prolotherapy anyway, and we owe it to our patients and ourselves to answer the question one way or the other.…”